[Palivizumab: four seasons in Russia].

In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization.

[Clinical-encephalographic evaluation of preterm children treated with cytoflavin during the first year of life].

An aim of the study was the clinical and neurophysiological evaluation of the effect of cytoflavin and reanimation measures on the rate of nervous and mental development of preterm newborns with cerebral ischemia, II--III stage, during the first year of life. One hundred and twenty children with gestational age 28--36 weeks and body mass 1060-3150 g were studied. In the main group (n=61), the complex treatment included cytoflavin in dosage 2 ml/kg/day, intravenously during 5 days. The control group (n=59) received basic treatment without cytoflavin. The follow-up till the age of 1 year comprised the global assessment of state and neurological status using quantitative measurements of muscle postural tone on the INFANIB scale, psychomotor development (BSID-II) and assessment of CNS functional state by analyzing computed EEG signals during physiological sleep. The results obtained demonstrated the fast normalization of all studied measures of development of children treated with cytoflavin compared to those of the control group.